Thursday, August 13

Browsing: HIF1β

Diagnosis

ARNT Expression Patterns Hold Promise for HIF-1β Inhibition in RCC Subtypes

By NewsCancerAugust 12, 20260

Investigating novel molecular targets across renal cell carcinoma (RCC) histologies remains critical to expanding precision oncology options. At the 2026…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

The dark side of DNA repair: when genome maintenance runs out of fuel

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression

Browsing: HIF1β

ARNT Expression Patterns Hold Promise for HIF-1β Inhibition in RCC Subtypes

The dark side of DNA repair: when genome maintenance runs out of fuel

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression

ARNT Expression Patterns Hold Promise for HIF-1β Inhibition in RCC Subtypes

The dark side of DNA repair: when genome maintenance runs out of fuel

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression

ARNT Expression Patterns Hold Promise for HIF-1β Inhibition in RCC Subtypes

Latest Post

The dark side of DNA repair: when genome maintenance runs out of fuel

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression

Subscribe to Updates

What's Hot

Browsing: HIF1β